Skip to main content
. 2021 Sep 1;25:323. doi: 10.1186/s13054-021-03744-w

Fig. 2.

Fig. 2

Boxplots displaying the median (centre line), IQR (outer limits of box), upper and lower limits (whiskers) and outlier observations (dots) for VAP incidence from groups with > 50% receiving MV where the identified microbe is Pseudomonas (a), Staphylococcus aureus (b), Acinetobacter (c) or Candida species (d) [data from between 113 and 191 studies (catalogued in [2427]). The overall benchmark (vertical green line) is the median derived from observational groups (green). Non-AB study is studies of non-antibiotic-based methods of infection prevention; TAP is topical antibiotic prophylaxis. Of note, the benchmark incidence for Pseudomonas VAP here (4.7 per 100 patients) is similar to that in a multi-centre survey [28]. The vertical blue lines are the Pseudomonas VAP incidence observed in ICU’s in Europe (4.8%), the USA (3.4%) and the Asia–pacific regions (3.2%) in the multi-centre survey [28]